HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

12th Edition of International Conference on Neurology and Brain Disorders

October 20-22, 2025

October 20 -22, 2025 | Orlando, Florida, USA

Botulinum Neurotoxins

Botulinum Neurotoxins

Botulinum Neurotoxins (BoNT's) are a family of thick-walled, heat-stable, highly potent toxins produced by the bacterium Clostridium botulinum and the related species C. butyricum and C. baratii. BoNT's are composed of a neurotoxic component (sometimes referred to as the 150 kD toxin) and one or more non-toxic components known as hemagglutinins or non-toxic proteins; both components are proteins. BoNT's block the release of acetylcholine at the neuromuscular junction, leading to a flaccid paralysis that affects muscles innervated by the affected neuron. The neurotoxic component of BoNT's is further divided into seven distinct serotypes (a, b, c (also known as d), e, f, g, h). Each serotype is antigenically distinct and has unique biological properties. BoNT's are potent inhibitors of acetylcholine release; they act by sequestering the vesicular form of the neurotransmitter in synaptic vesicles and preventing its release into the synapse upon binding to the medium-chain zinc-binding proteins known as synaptobrevin-2 and synaptotagmin. In this manner, BoNT's inhibit acetylcholine release between presynaptic and postsynaptic neurons. Inhibiting acetylcholine release from presynaptic axon terminals with BoNT's results in decreased muscle activity in the affected muscle, resulting in the flaccid paralysis that is observed. The duration of this paralysis is related to several factors, including the amount and type of BoNT injected, the dosage of BoNT, the muscle group affected, and the presence of physiologic conditions that may affect toxin uptake or action. BoNT's are highly selective toxins that, when used in clinical settings, performed at very low doses, can produce localized paralysis in a specified muscle or group of muscles with minimal systemic toxicity. BoNT's are most commonly used in the treatment of movement disorders, such as dystonia and spasticity, as well as cosmetic treatments such as treating wrinkles. They have also been found to be useful in the treatment of a number of conditions, such as migraine headaches, incontinence, excessive sweating, and jaw-clenching.

Committee Members
Speaker at Neuroscience Conference - Ken Ware

Ken Ware

NeuroPhysics Therapy Institute and Research Centre, Australia
Speaker at Neurology and Brain Disorders - Joe Sam Robinson

Joe Sam Robinson

Mercer University, United States
Speaker at Neurology Conferences - Robert B Slocum

Robert B Slocum

University of Kentucky HealthCare, United States
INBC 2025 Speakers
Speaker at Brain Disorders Conference - Thomas J Webster

Thomas J Webster

Interstellar Therapeutics, United States
Speaker at Neuroscience Conference - Roger H Coletti

Roger H Coletti

Interventional Health, PA, United States
Speaker at Neuroscience Conference - Stephen Grossberg

Stephen Grossberg

Boston University, United States
Speaker at Brain Disorders Conference - George Diaz

George Diaz

Memorial Healthcare Systems, United States

Submit your abstract Today

Watsapp